Vir Biotechnology Inc

+0.01 (+0.02%)
: $41.12 -0.16 (-0.39%)

GSK, Vir Submit EUA Request To FDA For Vir-7831 For Early Treatment Of COVID-19

Published: 03/26/2021 12:42 GMT
Vir Biotechnology Inc (VIR) - Gsk and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for Vir-7831 for Early Treatment of Covid-19.
Gsk - Co, Vir to Continue Talks With Ema and Other Global Regulators to Make Vir-7831 Available to Patients With Covid-19 As Soon As Possible.
Gsk - FDA Eua Submission is Based on Interim Analysis of Efficacy and Safety Data From Phase 3 Comet-ice Trial.
Gsk - Preclinical Data Suggest Vir-7831 Targets Highly Conserved Epitope of Spike Protein, Which May Make It More Difficult for Resistance to Develop.
Gsk- FDA Eua Submission for Vir-7831 to Treat Adults, Adolescents With Mild-to-moderate Covid-19 Who Are at Risk for Progression to Hospitalisation/death.
Gsk - Based on Additional Soon to Be Published Preclinical Data, Vir-7831 Also Appears to Maintain Activity Against the California Variant.